JAGX Stock Analysis: Buy, Sell, or Hold?
JAGX - Jaguar Health, Inc.
$2.17
-0.08 (-3.56%)
▼
5d:
-18.42%
30d:
-22.91%
90d:
+456.41%
HOLD
MODERATE Confidence
Analysis Updated: Jul 14, 2026 12:00 AM ET
Earnings: Aug 13, 2026
29d
Get Alerted When JAGX Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
1 traders called JAGX this week
17% bullish • 5 bearish
17% bullish • 5 bearish
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
📊 HOLD: JAGX shows balanced signals. Fine to hold or accumulate slowly. Monitor for clearer direction.
📊 HOLD: JAGX shows balanced signals. Fine to hold or accumulate slowly. Monitor for clearer direction.
In-depth Analysis How we analyze
Valuation Analysis: JAGX is currently trading at $2.17, which is considered oversold relative to its 30-day fair value range of $2.38 to $2.88.
Technical Outlook: Technically, JAGX is in a uptrend. The price is currently testing key support at $2.56. A bounce from this level would confirm strength, while a break below could signal further downside. Short-term momentum is weak, with the stock down 3.6% recently.
Market Sentiment: JAGX has a weak technical setup (25/100), with bearish trendlines and momentum suggesting caution for short-term entries. Wall Street analysts see significant upside, with an average price target of $262.50 (+11566.7%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Technical Outlook: Technically, JAGX is in a uptrend. The price is currently testing key support at $2.56. A bounce from this level would confirm strength, while a break below could signal further downside. Short-term momentum is weak, with the stock down 3.6% recently.
Market Sentiment: JAGX has a weak technical setup (25/100), with bearish trendlines and momentum suggesting caution for short-term entries. Wall Street analysts see significant upside, with an average price target of $262.50 (+11566.7%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Quick Decision Summary
Current Position
OVERSOLD
Historical Trading Range
$2.38 -
$2.88
Company Quality Score
45/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
52.6%
All Signals
- BULLISH: Price oversold vs 30-day range
- BEARISH: Weak technical setup (25/100)
- BULLISH: High volume confirmation
- BEARISH: Downward momentum (-3.6%)
- BULLISH: Trading 11566.7% below Wall St target ($262.50)
- CAUTION: 5-day price weakness (-18.4%) - monitor closely
Trading Range Analysis
30-Day Trading Range
$2.38 -
$2.88
Current vs Trading Range
OVERSOLD
Support & Resistance Levels
Support Level
$2.56
Resistance Level
$3.66
Current Trend
Uptrend
Technical data as of
Jun 9, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-0.24
Wall Street Target
$262.50
(+11566.7%)
Revenue Growth (YoY)
815.6%
Profit Margin
-115.4%
Share & Embed Analysis
Last updated: July 14, 2026 4:10 PM ET
Data refreshes hourly during market hours. Next update: 5:10 PM
Data refreshes hourly during market hours. Next update: 5:10 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is JAGX showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
ONC
BeiGene, Ltd. |
STRONG BUY
24 analysts |
$413 | 54 HOLD |
|
INSM
Insmed Inc |
STRONG BUY
21 analysts |
$197 | 54 HOLD |
|
VKTX
Viking Therapeutics Inc |
STRONG BUY
19 analysts |
$93 | 61 BUY |
|
BNTX
BioNTech SE |
STRONG BUY
21 analysts |
$122 | 52 HOLD |
|
APLS
Apellis Pharmaceuticals … |
BUY
22 analysts |
$41 | 59 HOLD |
